183 related articles for article (PubMed ID: 11031398)
1. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group.
Vicari RM; Wan GJ; Aura AM; Alexander CM; Markson LE; Teutsch SM
Arch Fam Med; 2000; 9(9):898-905. PubMed ID: 11031398
[TBL] [Abstract][Full Text] [Related]
2. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
Averna M; Zaninelli A; Le Grazie C; Gensini GF
J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
Molcányiová A; Stancáková A; Javorský M; Tkác I
Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease.
van Dam MJ; Penn HJ; den Hartog FR; Kragten HA; Trip MD; Buirma RJ; Kastelein JJ;
Clin Ther; 2001 Mar; 23(3):467-78. PubMed ID: 11318080
[TBL] [Abstract][Full Text] [Related]
8. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
Garmendia F; Brown AS; Reiber I; Adams PC
Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
[TBL] [Abstract][Full Text] [Related]
9. Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.
Magán-Fernández A; Papay-Ramírez L; Tomás J; Marfil-Álvarez R; Rizzo M; Bravo M; Mesa F
J Periodontol; 2014 Oct; 85(10):1408-15. PubMed ID: 24555750
[TBL] [Abstract][Full Text] [Related]
10. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
Stacy TA; Egger A
J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
[TBL] [Abstract][Full Text] [Related]
11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
12. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
14. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
16. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of simvastatin in patients with hypercholesterolemia (results of a Multicenter Clinical Study)].
Kukharchuk VV; Bubnova MG; Katel'nitskaia LI; Nikitin IuP; Ol'binskaia LI;
Kardiologiia; 2003; 43(5):42-7. PubMed ID: 12891239
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.
García-de-la-Puente S; Arredondo-García JL; Gutiérrez-Castrellón P; Bojorquez-Ochoa A; Maya ER; Pérez-Martínez Mdel P
Pediatr Nephrol; 2009 Jun; 24(6):1205-10. PubMed ID: 19238452
[TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
Stein E; Plotkin D; Bays H; Davidson M; Dujovne C; Korenman S; Stepanavage M; Mercuri M
Am J Cardiol; 2000 Aug; 86(4):406-11. PubMed ID: 10946033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
